Article

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hosts

2023-10-09

Abstract excerpt

<h4>Background: </h4> Immunocompromised patients with COVID-19 have higher morbidity and mortality than general population. Some authors have successfully used antiviral combination, but never in the early phase of the infection. <h4>Methods: </h4>: Retrospective cohort study to describe efficacy and safety of the combination of 2 antivirals, with or without a mAb, both in early (within 10 days from symptoms) and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9bb89b7b-6641-55f4-b062-2fc5687c3e1f
DOI: 10.21203/rs.3.rs-3402957/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsDOI 10.21203/rs.3.rs-3402957/v1Read

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity Read

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity Read

COVID 19 in Patients With Primary ImmunodeficiencySemantic proximity Read

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.Semantic proximity Read

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity Read

Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron SurgeSemantic proximity Read

Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case ReportSemantic proximity Read

An Overview on Drug Evolution and Trials on Pandemic COVID-19 InfectionSemantic proximity Read

Oral antivirals for COVID-19 among patients with cancerSemantic proximity Read

Real-world Effectiveness of Casirivimab Plus Indevimab in a Dedicated Ambulatory Unit Created for Patients With Early COVID During a Massive Delta Variant WaveSemantic proximity Read

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of ConcernSemantic proximity Read